Synthetic Biologics Stock Price, News & Analysis (NYSEAMERICAN:SYN)

$0.52 0.03 (5.25 %)
(As of 01/21/2018 04:00 PM ET)
Previous Close$0.52
Today's Range$0.50 - $0.53
52-Week Range$0.41 - $1.05
Volume890,844 shs
Average Volume900,703 shs
Market Capitalization$67.02 million
P/E Ratio-2.37
Dividend YieldN/A

About Synthetic Biologics (NYSEAMERICAN:SYN)

Synthetic Biologics logoSynthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Its other product candidates include SYN-007, SYN-006, SYN-005, SYN-200 and SYN-020. The Company is also developing preclinical-stage monoclonal antibody therapies for the prevention and treatment of pertussis, and discovery-stage biotherapeutics for the treatment of phenylketonuria (PKU).

Receive SYN News and Ratings via Email

Sign-up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E Ratio-2.36818181818182
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPS($0.22)
Net IncomeN/A
Net MarginsN/A
Return on Equity-340,418.40%
Return on Assets-224.71%


Outstanding Shares128,570,000

Synthetic Biologics (NYSEAMERICAN:SYN) Frequently Asked Questions

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics Inc (NYSEAMERICAN:SYN) posted its quarterly earnings data on Wednesday, November, 1st. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.10. View Synthetic Biologics' Earnings History.

Where is Synthetic Biologics' stock going? Where will Synthetic Biologics' stock price be in 2018?

1 analysts have issued 12 month price targets for Synthetic Biologics' shares. Their forecasts range from $5.00 to $5.00. On average, they expect Synthetic Biologics' share price to reach $5.00 in the next year. View Analyst Ratings for Synthetic Biologics.

Are investors shorting Synthetic Biologics?

Synthetic Biologics saw a drop in short interest in the month of December. As of December 29th, there was short interest totalling 4,416,270 shares, a drop of 9.7% from the December 15th total of 4,891,688 shares. Based on an average trading volume of 749,882 shares, the short-interest ratio is presently 5.9 days. Currently, 3.8% of the company's stock are short sold.

Who are some of Synthetic Biologics' key competitors?

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the folowing people:

  • Steven A. Shallcross, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary (Age 52)
  • Joseph A. Sliman, Chief Medical Officer (Age 44)
  • Jeffrey J. Kraws, Non-Executive Independent Chairman of the Board (Age 53)
  • Scott L. Tarriff, Independent Director (Age 57)
  • Jeffrey Alan Wolf J.D., Independent Director (Age 53)

How do I buy Synthetic Biologics stock?

Shares of Synthetic Biologics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synthetic Biologics' stock price today?

One share of Synthetic Biologics stock can currently be purchased for approximately $0.52.

How big of a company is Synthetic Biologics?

Synthetic Biologics has a market capitalization of $67.02 million.

How can I contact Synthetic Biologics?

Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at +1-734-3327800.

MarketBeat Community Rating for Synthetic Biologics (SYN)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  295
MarketBeat's community ratings are surveys of what our community members think about Synthetic Biologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Synthetic Biologics (NYSEAMERICAN:SYN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score:
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.00$5.50$5.50$5.45
Price Target Upside: 863.39% upside959.73% upside959.73% upside950.10% upside

Synthetic Biologics (NYSEAMERICAN:SYN) Consensus Price Target History

Price Target History for Synthetic Biologics (NYSEAMERICAN:SYN)

Synthetic Biologics (NYSEAMERICAN:SYN) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
5/22/2017William BlairReiterated RatingOutperform$5.00View Rating Details
1/14/2017FBR & CoReiterated RatingOverweight$6.00View Rating Details
11/25/2016LaurentianDowngradeBuy -> Speculative BuyView Rating Details
11/25/2016Laurentian Bank of CanadaDowngradeBuy -> Speculative BuyView Rating Details
8/31/2016Griffin SecuritiesSet Price TargetBuy$9.00 -> $5.80View Rating Details
8/25/2016BTIG ResearchInitiated CoverageBuy$5.00View Rating Details
2/5/2016Royal Bank of CanadaReiterated RatingOutperform$8.00View Rating Details
(Data available from 1/21/2016 forward)


Synthetic Biologics (NYSEAMERICAN:SYN) Earnings History and Estimates Chart

Earnings by Quarter for Synthetic Biologics (NYSEAMERICAN:SYN)

Synthetic Biologics (NYSEAMERICAN SYN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017Q3 2017($0.04)($0.14)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.06)($0.03)ViewListenView Earnings Details
5/4/2017Q1 2017($0.07)($0.02)ViewListenView Earnings Details
3/2/2017Q4 2016($0.08)($0.02)ViewListenView Earnings Details
11/1/2016Q316($0.10)($0.09)ViewN/AView Earnings Details
8/3/2016Q2 2016($0.12)($0.10)ViewN/AView Earnings Details
5/5/2016Q116($0.13)($0.12)ViewN/AView Earnings Details
3/10/2016Q415($0.12)($0.12)ViewListenView Earnings Details
11/5/2015Q315($0.12)($0.12)ViewN/AView Earnings Details
8/10/2015Q215($0.11)($0.19)ViewListenView Earnings Details
5/11/2015Q115($0.08)($0.11)ViewListenView Earnings Details
3/16/2015($0.06)($0.09)ViewN/AView Earnings Details
11/14/2014Q314($0.05)($0.08)ViewN/AView Earnings Details
8/14/2014($0.06)($0.08)ViewN/AView Earnings Details
5/15/2014Q1 14($0.08)($0.07)ViewN/AView Earnings Details
3/31/2014($0.06)($0.09)ViewN/AView Earnings Details
11/14/2013Q3($0.06)($0.08)ViewListenView Earnings Details
8/14/2013Q2 2013($0.06)($0.06)ViewN/AView Earnings Details
5/15/2013Q1 2013($0.05)($0.05)ViewN/AView Earnings Details
11/14/2012Q3 2012($0.05)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.05)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.06)ViewN/AView Earnings Details
11/14/2011Q3 2011($0.04)ViewN/AView Earnings Details
8/15/2011Q2 2011($0.06)ViewN/AView Earnings Details
5/16/2011Q1 2011($0.09)ViewN/AView Earnings Details
3/31/2011Q4 2010($0.04)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.03)ViewN/AView Earnings Details
8/16/2010Q2 2010$0.04ViewN/AView Earnings Details
5/17/2010Q1 2010($0.05)ViewN/AView Earnings Details
11/16/2009Q3 2009($0.03)ViewN/AView Earnings Details
5/15/2009Q1 2009($0.01)ViewN/AView Earnings Details
4/1/2009Q4 2008($0.07)($0.04)ViewN/AView Earnings Details
8/14/2008Q2 2008($0.11)($0.09)ViewN/AView Earnings Details
5/15/2008Q1 2008($0.12)($0.15)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Synthetic Biologics (NYSEAMERICAN:SYN) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Synthetic Biologics (NYSEAMERICAN:SYN)

No dividend announcements for this company have been tracked by

Insider Trades

Synthetic Biologics (NYSEAMERICAN SYN) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Synthetic Biologics (NYSEAMERICAN:SYN)

Synthetic Biologics (NYSEAMERICAN SYN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/17/2015Brendan CannonDirectorBuy5,000$0.39$1,925.00
11/30/2015Christoper MartinDirectorBuy80,000$0.40$32,000.00
11/27/2015Bartley Vaden HeathDirectorBuy35,000$0.28$9,800.00
9/2/2015Randal J KirkMajor ShareholderBuy937,500$3.20$3,000,000.00View SEC Filing  
5/22/2014Charles Evan BallantyneCFOBuy10,000$1.35$13,500.00View SEC Filing  
4/29/2014Steve H KanzerDirectorSell263,112$2.90$763,024.80View SEC Filing  
12/17/2013Randal J KirkMajor ShareholderBuy2,500,000$1.00$2,500,000.00View SEC Filing  
1/7/2013Jeffrey Scott RileyCEOBuy2,900$0.17$493.00View SEC Filing  
1/3/2013Jeffrey Scott RileyCEOBuy2,000$1.71$3,420.00View SEC Filing  
10/29/2012Randal J KirkMajor ShareholderBuy3,125,000$1.60$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Synthetic Biologics (NYSEAMERICAN SYN) News Headlines

Synthetic Biologics Inc (SYN) Short Interest UpdateSynthetic Biologics Inc (SYN) Short Interest Update - January 11 at 1:22 AM
Synthetic Biologics to Present at the Biotech Showcase™ 2018 Conference - PR Newswire (press release)Synthetic Biologics to Present at the Biotech Showcase™ 2018 Conference - PR Newswire (press release) - January 2 at 9:33 PM
Synthetic Biologics to Present at the Biotech Showcase™ 2018 ConferenceSynthetic Biologics to Present at the Biotech Showcase™ 2018 Conference - January 2 at 4:33 PM
Synthetic Biologics Inc (SYN) Short Interest Down 13.1% in DecemberSynthetic Biologics Inc (SYN) Short Interest Down 13.1% in December - December 28 at 2:09 AM
Synthetic Biologics, Inc. (SYN) Short Interest Down 10.2% in NovemberSynthetic Biologics, Inc. (SYN) Short Interest Down 10.2% in November - December 12 at 1:50 AM
Synthetic Biologics Announces Management Changes - PR Newswire - PR Newswire (press release)Synthetic Biologics Announces Management Changes - PR Newswire - PR Newswire (press release) - December 5 at 3:29 PM
Synthetic Biologics, Inc. (SYN) Short Interest Down 12.6% in NovemberSynthetic Biologics, Inc. (SYN) Short Interest Down 12.6% in November - November 27 at 9:30 PM
ImmunoPrecise Realigns Senior ManagementImmunoPrecise Realigns Senior Management - November 20 at 10:41 AM

SEC Filings

Synthetic Biologics (NYSEAMERICAN:SYN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Synthetic Biologics (NYSEAMERICAN:SYN) Income Statement, Balance Sheet and Cash Flow Statement


Synthetic Biologics (NYSEAMERICAN SYN) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.